FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005954732> ?p ?o ?g. }

• W2005954732 endingPage "414" @default.
• W2005954732 startingPage "407" @default.
• W2005954732 abstract "Background The aim of this study was to evaluate strategies for assignment of HIV–HCV genotype-1-coinfected patients (HIV–HCV-GT1) to either dual-therapy or direct-acting antiviral agent (DAA)-based triple-therapy. Methods A total of 148 treatment-naive HIV–HCV-GT1 who received antiviral therapy with pegylated interferon/ ribavirin were included in this multinational, retrospective analysis. Patients with rapid virological response (RVR) were treated for 48 weeks, while patients without RVR received either 48 or 72 weeks of treatment. IL28B rs12979860 (IL28B) non-C/C, advanced liver fibrosis and high HCV RNA were considered as established risk factors for treatment failure. Results A trend toward higher sustained virological response (SVR) rates in patients with IL28B C/C (65% [37/57] versus 51% [40/79]; P=0.097) was observed. Higher SVR rates were observed in patients without advanced liver fibrosis (61% [47/77] versus 42% [22/52]); P=0.036) and without high HCV RNA (73% [35/48] versus 49% [49/100]; P=0.006), as well as in patients with RVR (90% [35/39] versus 45% [49/109]; P<0.001). SVR rates varied statistically significantly between the risk factors for treatment failure subgroups (86% [6/7] versus 69% [34/49] versus 48% [21/44] versus 20% [4/20] for zero, one, two and three risk factors, respectively; P<0.001). In patients without RVR, higher rates of SVR were observed in those treated for 72 weeks (62% [23/37]), when compared to patients treated for 48 weeks (36% [26/72]; P=0.01). Conclusions RVR had an excellent positive predictive value for the response to dual-therapy in HIV–HCV-GT1, emphasizing the utility of a lead-in phase for assigning these patients to dual-therapy or DAA-based triple-therapy. The use of an IL28B-guided approach was suboptimal, while a combination of established baseline predictors may provide guidance for individual treatment decisions prior to the initiation of antiviral therapy. However, the extension of treatment duration to 72 weeks in HIV–HCV-GT1 without RVR should be strongly considered if triple-therapy is not available." @default.
• W2005954732 created "2016-06-24" @default.
• W2005954732 creator A5001359223 @default.
• W2005954732 creator A5010288279 @default.
• W2005954732 creator A5018049535 @default.
• W2005954732 creator A5018983251 @default.
• W2005954732 creator A5041759120 @default.
• W2005954732 creator A5046120682 @default.
• W2005954732 creator A5046244856 @default.
• W2005954732 creator A5053492555 @default.
• W2005954732 creator A5054617732 @default.
• W2005954732 creator A5067570858 @default.
• W2005954732 creator A5070949389 @default.
• W2005954732 creator A5073880705 @default.
• W2005954732 creator A5082036366 @default.
• W2005954732 creator A5087316703 @default.
• W2005954732 date "2013-05-01" @default.
• W2005954732 modified "2023-10-15" @default.
• W2005954732 title "Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy" @default.
• W2005954732 cites W1540111651 @default.
• W2005954732 cites W1713033459 @default.
• W2005954732 cites W2005697115 @default.
• W2005954732 cites W2006286204 @default.
• W2005954732 cites W2009119799 @default.
• W2005954732 cites W2011124302 @default.
• W2005954732 cites W2025561586 @default.
• W2005954732 cites W2027498662 @default.
• W2005954732 cites W2034422153 @default.
• W2005954732 cites W2046658390 @default.
• W2005954732 cites W2062563125 @default.
• W2005954732 cites W2063964141 @default.
• W2005954732 cites W2084947696 @default.
• W2005954732 cites W2085652845 @default.
• W2005954732 cites W2090017919 @default.
• W2005954732 cites W2103638317 @default.
• W2005954732 cites W2104103604 @default.
• W2005954732 cites W2118771356 @default.
• W2005954732 cites W2125963799 @default.
• W2005954732 cites W2126662952 @default.
• W2005954732 cites W2129228826 @default.
• W2005954732 cites W2130871682 @default.
• W2005954732 cites W2141214317 @default.
• W2005954732 cites W2142007317 @default.
• W2005954732 cites W2143559032 @default.
• W2005954732 cites W2157607569 @default.
• W2005954732 cites W2161672461 @default.
• W2005954732 cites W2168229737 @default.
• W2005954732 cites W2170764256 @default.
• W2005954732 cites W2236174386 @default.
• W2005954732 cites W2292860810 @default.
• W2005954732 cites W4237167198 @default.
• W2005954732 doi "https://doi.org/10.3851/imp2717" @default.
• W2005954732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24342953" @default.
• W2005954732 hasPublicationYear "2013" @default.
• W2005954732 type Work @default.
• W2005954732 sameAs 2005954732 @default.
• W2005954732 citedByCount "4" @default.
• W2005954732 countsByYear W20059547322014 @default.
• W2005954732 countsByYear W20059547322021 @default.
• W2005954732 crossrefType "journal-article" @default.
• W2005954732 hasAuthorship W2005954732A5001359223 @default.
• W2005954732 hasAuthorship W2005954732A5010288279 @default.
• W2005954732 hasAuthorship W2005954732A5018049535 @default.
• W2005954732 hasAuthorship W2005954732A5018983251 @default.
• W2005954732 hasAuthorship W2005954732A5041759120 @default.
• W2005954732 hasAuthorship W2005954732A5046120682 @default.
• W2005954732 hasAuthorship W2005954732A5046244856 @default.
• W2005954732 hasAuthorship W2005954732A5053492555 @default.
• W2005954732 hasAuthorship W2005954732A5054617732 @default.
• W2005954732 hasAuthorship W2005954732A5067570858 @default.
• W2005954732 hasAuthorship W2005954732A5070949389 @default.
• W2005954732 hasAuthorship W2005954732A5073880705 @default.
• W2005954732 hasAuthorship W2005954732A5082036366 @default.
• W2005954732 hasAuthorship W2005954732A5087316703 @default.
• W2005954732 hasConcept C126322002 @default.
• W2005954732 hasConcept C167135981 @default.
• W2005954732 hasConcept C203014093 @default.
• W2005954732 hasConcept C2522874641 @default.
• W2005954732 hasConcept C2776408679 @default.
• W2005954732 hasConcept C2776455275 @default.
• W2005954732 hasConcept C2776461080 @default.
• W2005954732 hasConcept C2776999253 @default.
• W2005954732 hasConcept C2780040827 @default.
• W2005954732 hasConcept C71924100 @default.
• W2005954732 hasConcept C90924648 @default.
• W2005954732 hasConceptScore W2005954732C126322002 @default.
• W2005954732 hasConceptScore W2005954732C167135981 @default.
• W2005954732 hasConceptScore W2005954732C203014093 @default.
• W2005954732 hasConceptScore W2005954732C2522874641 @default.
• W2005954732 hasConceptScore W2005954732C2776408679 @default.
• W2005954732 hasConceptScore W2005954732C2776455275 @default.
• W2005954732 hasConceptScore W2005954732C2776461080 @default.
• W2005954732 hasConceptScore W2005954732C2776999253 @default.
• W2005954732 hasConceptScore W2005954732C2780040827 @default.
• W2005954732 hasConceptScore W2005954732C71924100 @default.
• W2005954732 hasConceptScore W2005954732C90924648 @default.
• W2005954732 hasIssue "4" @default.
• W2005954732 hasLocation W20059547321 @default.

• next